Profil bibliographique

Christopher Busse

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

49Publications signalées

218Citations signalées

2Affiliations récentes

Institutions déclarées

Johnson & Johnson (United States)Janssen (Switzerland)

Domaines associés

Inflammatory Bowel DiseasePharmaceutical studies and practicesImmunodeficiency and Autoimmune DisordersAdolescent and Pediatric HealthcareMicroscopic Colitis

Publications récentes

2025 conference-abstractOpenAlex

S1454 Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients With Moderately to Severely Active Crohn’s Disease and Inadequate Response to Ustekinumab: Results From GALAXI 1, 2, & 3 Long-Term Extension

Anita Afzali, Douglas C. Wolf, Rupert W. Leong, Rian Van Rampelbergh et autres

0 citationsThe American Journal of Gastroenterology

Accès ouvert 2025 articleOpenAlex

Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease

Stefan Schreiber, Scott D. Lee, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

2 citationsInflammatory Bowel Diseases

2025 conference-abstractOpenAlex

Tu1904: TREATMENT DISCONTINUATION IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN’S DISEASE RECEIVING BIOLOGIC THERAPIES THAT REQUIRE INTRAVENOUS INFUSIONS DURING INDUCTION AND SUBCUTANEOUS INJECTIONS DURING MAINTENANCE

Jennifer Seminerio, Yan Wang, Aolin Wang, Shuang Wang et autres

0 citationsGastroenterology

Accès ouvert 2025 conference-abstractOpenAlex

P0891 Efficacy and safety of subcutaneous guselkumab rescue therapy in patients with moderately to severely active Crohn’s disease and inadequate response to ustekinumab: Phase 2 GALAXI 1 study long-term extension results

Anita Afzali, Douglas C. Wolf, Rupert W. Leong, L Salese et autres

1 citationJournal of Crohn s and Colitis

2024 conference-abstractOpenAlex

S1428 Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients With Moderately to Severely Active Crohn’s Disease and Inadequate Response to Ustekinumab: Phase 2 GALAXI 1 Study Long-Term Extension Results

Anita Afzali, Douglas C. Wolf, Rupert W. Leong, Leonardo Salese et autres

1 citationThe American Journal of Gastroenterology

2024 conference-abstractOpenAlex

Mo2037 USTEKINUMAB IN DEVELOP: A SAFETY ANALYSIS FROM AN INFLAMMATORY BOWEL DISEASE MULTICENTER, PROSPECTIVE, LONG-TERM REGISTRY OF PEDIATRIC PATIENTS

Sibylle Koletzko, Gigi Veereman, Jeffrey S. Hyams, Marla C. Dubinsky et autres

0 citationsGastroenterology

Accès ouvert 2024 articleOpenAlex

P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients

Sibylle Koletzko, Gigi Veereman, Jeffrey S. Hyams, Marla C. Dubinsky et autres

0 citationsJournal of Crohn s and Colitis

2023 conference-abstractOpenAlex

S842 Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn’s Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study

Brian G. Feagan, Scott D. Lee, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

0 citationsThe American Journal of Gastroenterology

2023 conference-abstractOpenAlex

S1035 Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn’s Disease in the POWER Trial

Douglas C. Wolf, Scott D. Lee, Stefan Schreiber, C. Janneke van der Woude et autres

0 citationsThe American Journal of Gastroenterology

2023 conference-abstractOpenAlex

S1073 Clinical Outcomes and Biomarker Normalization Response at Week 16 in Patients With Inadequate Response or Intolerance to Prior Biologics in the POWER Trial

Scott D. Lee, Stefan Schreiber, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

0 citationsThe American Journal of Gastroenterology

2023 articleOpenAlex

Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response during ustekinumab maintenance therapy: week 16 results from the phase 3b POWER trial

Stefan Schreiber, S. Lee, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

0 citationsZeitschrift für Gastroenterologie

2023 articleOpenAlex

1027 EFFICACY AND SAFETY OF INTRAVENOUS USTEKINUMAB REINDUCTION THERAPY IN CROHN'S DISEASE PATIENTS WITH SECONDARY LOSS OF RESPONSE TO USTEKINUMAB MAINTENANCE THERAPY: WEEK 16 RESULTS FROM THE POWER TRIAL

Scott D. Lee, Stefan Schreiber, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

3 citationsGastroenterology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.